Trabalho de evento-resumo periodico

Phase 3, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: BOLERO-1 (2015)

• Authors:
  • Hurvitz, Sara A.
  • Andre, Fabrice
  • Jiang, Zefei
  • Shao, Zhimin
  • Neciosup, Silvia P.
  • Mano, Max S.
  • Tseng, Ling-Min
  • Zhang, Qingyuan
  • Shen, Kunwei
  • Liu, Donggeng
  • Dreosti, Lydia M.
  • Feng, Jifeng
  • Burris, Howard A.
  • Toi, Masakazu
  • Buyse, Marc E.
  • Cabaribere, David
  • Lindsay, Mary-Ann
  • Kunz, Tiffany
  • Rao, Shantha
  • Pacaud, Lida B.
  • Taran, Tetiana
  • Slamon, Dennis
• Autor USP: MANO, MAX SENNA - FM
• Unidade: FM
• DOI: 10.1158/1538-7445.SABCS14-S6-01
• Subjects: PLACEBO; NEOPLASIAS MAMÁRIAS (FISIOPATOLOGIA); ESTUDOS RANDOMIZADOS
• Language: Inglês
• Imprenta:
  • Publisher place: Baltimore
  • Date published: 2015
• Source:
  • Título do periódico: Cancer Research
  • ISSN: 0008-5472
  • Volume/Número/Paginação/Ano: v. 75, abst. S6-01, May, 2015
• Conference titles: Annual CTRC-AACR San Antonio Breast Cancer Symposium

Informações sobre o DOI: 10.1158/1538-7445.SABCS14-S6-01 (Fonte: oaDOI API)
• Este periódico é de assinatura
• Este artigo NÃO é de acesso aberto
  
• Cor do Acesso Aberto: closed

---

How to cite

A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

• ABNT

  HURVITZ, Sara A. et al. Phase 3, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: BOLERO-1. Cancer Research. Baltimore: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1158/1538-7445.SABCS14-S6-01. Acesso em: 24 abr. 2024. , 2015

• APA

  Hurvitz, S. A., Andre, F., Jiang, Z., Shao, Z., Neciosup, S. P., Mano, M. S., et al. (2015). Phase 3, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: BOLERO-1. Cancer Research. Baltimore: Faculdade de Medicina, Universidade de São Paulo. doi:10.1158/1538-7445.SABCS14-S6-01

• NLM

  Hurvitz SA, Andre F, Jiang Z, Shao Z, Neciosup SP, Mano MS, Tseng L-M, Zhang Q, Shen K, Liu D, Dreosti LM, Feng J, Burris HA, Toi M, Buyse ME, Cabaribere D, Lindsay M-A, Kunz T, Rao S, Pacaud LB, Taran T, Slamon D. Phase 3, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: BOLERO-1 [Internet]. Cancer Research. 2015 ; 75[citado 2024 abr. 24 ] Available from: https://doi.org/10.1158/1538-7445.SABCS14-S6-01

• Vancouver

  Hurvitz SA, Andre F, Jiang Z, Shao Z, Neciosup SP, Mano MS, Tseng L-M, Zhang Q, Shen K, Liu D, Dreosti LM, Feng J, Burris HA, Toi M, Buyse ME, Cabaribere D, Lindsay M-A, Kunz T, Rao S, Pacaud LB, Taran T, Slamon D. Phase 3, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: BOLERO-1 [Internet]. Cancer Research. 2015 ; 75[citado 2024 abr. 24 ] Available from: https://doi.org/10.1158/1538-7445.SABCS14-S6-01

Últimas obras dos mesmos autores vinculados com a USP cadastradas na BDPI:

• Value of systemic staging in asymptomatic early breast cancer
• Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial
• Reply to [Carta]: mastectomy skin flap thickness
• A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American Cooperative Oncology Group 0801 Study)
• HER2-targeted therapy in breast cancer: A systematic review of neoadjuvant trials
• Return to work after breast cancer diagnosis: An observational prospective study of 125 patients in South America
• O uso do Oncotype DX® na indicação de quimioterapia adjuvante - experiência do Hospital Sírio-Libanês
• Pneumonite não-infecciosa em paciente com tumor neuroendócrino tratado com everolimus (EVR)
• Multidisciplinary international survey of post-operative radiation therapy practices after nipple-sparing or skin-sparing mastectomy
• Rare tumors research in emerging countries